Background {#Sec1}
==========

Insulin-like growth factors (IGFs) have been used in the diagnosis of growth hormone (GH) deficiency, to monitor the impact of GH replacement therapy on growth and to assess treatment compliance and safety \[[@CR1], [@CR2]\]. Monitoring the impact of GH treatment on growth is mainly based on measurement of serum IGF-I levels, and less often on IGF-binding protein 3 (IGFBP3) levels and the IGF-I/IGFBP3 ratio. Rudman et al. were the first to report the relationship between short-term IGF-I increments and GH growth response \[[@CR3]\]. Further short-duration studies in prepubertal children conducted by different groups found an increase in IGF-I from baseline to be a reliable sign of greater growth in response to GH \[[@CR4]--[@CR7]\]. Only two studies reported results for multiple variables (IGF-I, IGFBP3 and their molar ratio). These were non-randomized, 1-year clinical trials in prepubertal children with and without GH deficiency (GHD) \[[@CR8], [@CR9]\]. They both observed an increase in IGFs during GH treatment as a sign of high GH sensitivity and treatment compliance. To our knowledge, the relevance of the variables IGF-I, IGFBP3 and the IGF-I/IGFBP3 ratio in relation to prepubertal, pubertal and total gain in height has not been previously reported in GH-treated children.

Under normal conditions, serum IGF-I level increases slowly during childhood before rising to a peak in puberty. This peak correlates with pubertal stage due to the action of sex steroids to increase GH secretion \[[@CR10]--[@CR13]\]. Factors explaining pubertal growth in response to GH therapy: gender, age, the difference between the child's height standard deviation score (SDS) and midparental height~SDS~ (diffH-MPH) at the onset of puberty, and GH dose were identified from the KIGS observational study, but the IGF-I variable was not available in that study \[[@CR14]\]. There have only been two published randomized trials in GH-deficient pubertal children on GH treatment receiving different GH doses. Both reported a greater pubertal height gain in high GH-dose groups (50--100 μg/kg/d) accompanied by an increase in IGF-I \[[@CR15], [@CR16]\]. Our group has recently published results from a randomized study in non-GH-deficient children followed from early puberty to adult height (AH): data show the greater the increase in IGF-I, the greater the gain in height \[[@CR17]\]. In children with low GH secretion diagnosed with idiopathic isolated GHD (IIGHD), we have also reported that GH dosing, mimicking the physiological pubertal increase in GH secretion, has a dose-dependent effect on the gain in height~SDS~ until AH. In this randomized GH-treatment trial, pubertal height gain~SDS~ and AH~SDS~ were greater in children randomized to a high GH dose (67 μg/kg/d) than a standard dose (33 μg/kg/d) \[[@CR18], [@CR19]\]. The hypothesis of the present analysis of prospectively collected data in the aforementioned clinical trial was that the IGFs would follow the normal pubertal change in GH-deficient children receiving a higher, more physiological, GH dose during puberty. The secondary aim was to explore the relationship between serum IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 ratio and gain in height until AH.

Patients and methods {#Sec2}
====================

Ethics {#Sec3}
------

The study (TRN number 88--177) was approved by the Ethics Committees at the Universities of Gothenburg, Lund, Linköping, Uppsala, Huddinge and Umeå and by the Karolinska Institute (dnr LU 426--1988). Informed consent was obtained from the children and their parents verbally with written registration date in the patients' medical file.

Study design {#Sec4}
------------

The study was a nationwide, randomized, multicenter trial conducted from 1988 to 2009 and its design has been described previously \[[@CR18], [@CR19]\]. In brief, all children with IIGHD had received GH at a dose of 33 μg/kg for at least 1 year prior to the onset of puberty. After the development of clinical signs of puberty, the children were allocated randomly, without stratification, into three dose groups: 33 μg/kg once daily (GH^33x1^); 67 μg/kg once daily (GH^67x1^) or 33 μg/kg twice daily (GH^33x2^). The children were followed until AH (the observed height at a growth rate of \< 1 cm during the preceding 12 months). They were seen at least once a year at a university hospital to monitor treatment safety and efficacy and at their local children's hospital at 3-monthly intervals.

GH dose reduction {#Sec5}
-----------------

In line with the protocol, it was accepted that any patient could reduce GH dose or stop treatment if he/she was satisfied with the height development. The reduced doses used were 25 % less than the randomized dose (doses were 50 μg/kg/d and 25 μg/kg/d for the high and low dose groups, respectively). In the intention-to-treat (ITT) population the GH dose was reduced in 35 children and GH treatment was stopped in 5 children; this affected 44 % of children in the high dose and 29 % in the standard dose groups. For efficacy analyses, only IGF-I~SDS~ levels obtained during treatment with the randomized dose were used, but for safety analyses all IGF-I~SDS~ measurements were used.

Patients {#Sec6}
--------

### Inclusion and exclusion criteria {#Sec7}

All patients were diagnosed with IIGHD in the 1980s. GH deficiency was diagnosed based on a GH response cut off corresponding to "10 μg/L" \[[@CR20], [@CR21]\] in two GH provocation tests, mainly the arginine--insulin tolerance test (AITT). A positive response to GH treatment was also an inclusion criterion. This was ascertained by an increase in height velocity of at least 50 % during the first prepubertal year of GH treatment (33 μg/kg/d). IGF-I, IGFBP3 and the IGF-I/IGFBP3 ratio~SDS~ were measured but were not required for diagnosis. Children with any hormone insufficiency in addition to GH or with significant chronic diseases or syndromes were excluded from the study.

### Safety population {#Sec8}

The study population has been described previously \[[@CR19]\]. Briefly: a total of 149 (116 boys) short children (\< −2SDS) with low GH~max~ during AITT (GH~max~AITT) were enrolled in the study between 1989 and 2000 and form the safety population. Of the enrolled children, 38 were excluded from efficacy analyses due to protocol violation/wrong inclusion: 1 child had a bone age (BA) delay of 3.6 years at GH start, 24 children were already pubertal (breast \> 1, testes \> 8 ml) at or within 1 year after GH start and 1 child was lost from follow-up. Moreover, 6 children who were born at a gestational age \< 32 weeks and 6 adopted children with missing information at birth were excluded from the present analyses. Seven further children (6 boys) for whom most IGF-I data were missing were also excluded from the present analysis.

### ITT/PP population {#Sec9}

The remaining 104 children (90 boys) constituted the ITT population of whom 95 (82 boys) comprised the per-protocol (PP) population.

Of the 9 children (8 boys) not belonging to the PP population, 5 boys had stopped GH treatment prematurely (\<2.25 years after study start and before AH was reached) and 4 children (3 boys) on GH^67^ decreased their GH dose to GH^33x1^

When the study group was divided into the groups to which they were later randomized, there were no differences in IGF levels between the groups. Moreover, there were no differences in IGF-I levels at baseline between boys and girls.

Methods {#Sec10}
=======

Hormone measurements {#Sec11}
--------------------

*Serum IGF-I and IGFBP3* levels were measured using an IGFBP-blocked radioimmuno assay (RIA) with an excess of IGF-II for determination of IGF-I, and a specific RIA for IGFBP3 (Mediagnost GmbH, Tübingen, Germany). The intra-assay coefficients of variation (CVs) for the IGF-I assay were 11.1, 7.2 and 7.4 % at concentrations of 36, 204 and 545 μg/L, respectively; the interassay CVs for the same concentrations were 13.5, 8.8, and 9.9 %, respectively. For the IGFBP3 assay, the intra-assay CVs were 7.1, 7.3, and 7.9 % at concentrations of 1800, 3790 and 5776 μg/L, respectively; the interassay CVs for the same concentrations were 13.4, 10.5 and 14.1 %, respectively. Results were converted into SDS according to age, sex and pubertal stage, and the ratio~SDS~ of IGF-I to IGFBP3 was calculated \[[@CR12], [@CR22]\]. IGF-I and IGFBP3 were analyzed before and after the initiation of GH treatment (+10 days, +1 month, +3 months, +1 year and annually thereafter). For the purpose of the present analyses, mean pubertal IGF-I~SDS~, IGFBP3~SDS~ and IGF-I/IGFBP3 ratio~SDS~ were calculated based on individual mean levels in the time period from 12 months after study start to treatment stop. The change in level was defined as the mean level (as calculated above) minus the level at study start. The prepubertal mean IGF-I~SDS~, IGFBP3~SDS~, and IGF-I/IGFBP3 ratio~SDS~ were based on data collected in the time period from 1 year after GH start until the clinical onset of puberty. All samples from each individual were analyzed at the same time.

### Growth hormone {#Sec12}

GH~max~ was assessed using both the AITT and a spontaneous 24-h GH secretion profile \[[@CR20], [@CR21]\]. GH concentrations were analysed with polyclonal antibodies, and for comparison, all measurements were converted to the WHO standard international reference preparation 80/505, even if measured with 66/127 \[[@CR20]\].

### Growth outcome {#Sec13}

The outcomes used for evaluation of growth response were: prepubertal, pubertal and total gain in height~SDS~ calculated as previously described \[[@CR19], [@CR23]\].

*Pubertal gain in height*~*SDS*~ was defined as AH~SDS~ minus last recorded pre-pubertal height~SDS,~ the SDS estimated with the childhood component of the total reference \[[@CR23], [@CR24]\].

*Prepubertal gain in height*~*SDS*~ was defined as height~SDS~ at last pre-pubertal visit minus height~SDS~ at GH start using the childhood component of the total reference \[[@CR24]\].

*Total gain in height*~*SDS*~ was calculated using AH~SDS~ (adult height in cm transferred into SDS for age 18 years) minus height~SDS~ at GH start, using the prepubertal childhood component of the total growth reference \[[@CR23], [@CR24]\].

There were no differences in gain in height~SDS~ between the two high-dose groups with GH^67^ given once or divided into twice daily GH^33^ (Table [1](#Tab1){ref-type="table"}); therefore, the results from the high-dose groups are presented combined (GH^67+33x2^).Table 1Growth characteristics at adult height according to randomization groupAt Adult Height33 × 167 × 133 × 267 × 1 + 33 × 2*n* = 38*n* = 30*n* = 36*n* = 66ITT all, *n* = 104Mean ± SDMean ± SDMean ± SDMean ± SDAge, years18.6 ± 1.518.6 ± 1.2718.6 ± 1.7918.6 ± 1.56Adult height~SDS~−1.2 ± 0.68−0.9 ± 0.93−0.8 ± 0.88−0.8 ± 0.89diffH-MPH~SDS~0.2 ± 0.800.3 ± 1.130.2 ± 1.000.2 ± 1.05Total gain in height~SDS~1.6 ± 0.832.1 ± 1.14^\*^1.9 ± 0.822.0 ± 0.97^\*^Prepubertal gain in height~SDS~1.2 ± 0.851.4 ± 1.281.2 ± 0.711.3 ± 1.00Pubertal gain in height~SDS~0.4 ± 0.580.7 ± 0.900.7 ± 0.770.7 ± 0.83^\*^Years from puberty5.7 ± 1.225.5 ± 1.515.9 ± 1.585.7 ± 1.55Years from GH start8.5 ± 2.878.7 ± 3.218.9 ± 2.928.8 ± 3.03Years on GH7.6 ± 2.887.7 ± 2.997.7 ± 3.047.7 ± 2.99Years in study5.1 ± 1.244.9 ± 1.485.1 ± 1.545.0 ± 1.50PP, boys, *n* = 82*n* = 34*n* = 23*n* = 25*n* = 48Age, years18.7 ± 1.4218.8 ± 1.1418.8 ± 1.8918.8 ± 1.56Adult height~SDS~−1.2 ± 0.60−0.8 ± 0.84−0.8 ± 0.93−0.8 ± 0.88diffH-MPH~SDS~0.2 ± 0.820.4 ± 1.050.2 ± 1.000.3 ± 1.02Total gain in height~SDS~1.5 ± 0.692.0 ± 0.88^\*^1.9 ± 0.75a1.9 ± 0.81^\*\*^Prepubertal gain in height~SDS~1.00 ± 0.611.1 ± 0.581.2 ± 0.741.1 ± 0.67Pubertal gain in height~SDS~0.4 ± 0.600.9 ± 0.88^\*^0.7 ± 0.750.8 ± 0.81^\*^Years from puberty5.7 ± 1.185.6 ± 1.556.2 ± 1.815.9 ± 1.7Years from GH start8.3 ± 2.628.5 ± 2.989.1 ± 3.258.8 ± 3.11Years on GH7.5 ± 2.627.5 ± 2.788.0 ± 3.167.8 ± 2.96Years in study5.1 ± 1.164.9 ± 1.455.4 ± 1.735.1 ± 1.6ITT, Girls, *n* = 14*n* = 3*n* = 5*n* = 6*n* = 11Age, years16.7 ± 1.4617.2 ± 1.1417.3 ± 1.3117.2 ± 1.18Adult height~SDS~0.0 ± 0.49−0.6 ± 0.94−1.3 ± 0.71^\*^−1.0 ± 0.87diffH-MPH~SDS~0.2 ± 0.500.3 ± 0.95−0.2 ± 0.960.0 ± 0.94Total gain in height~SDS~3.0±0.983.1±1.801.6±0.972.2±1.54Prepubertal gain in height~SDS~2.9±1.503.1±2.291.1±0.512.0±1.83Pubertal gain in height~SDS~0.3±0.33−0.1±0.710.4±0.890.2±0.82Years from puberty4.5±0.545.8±1.555.6±0.915.7±1.18Years from GH start10.8±5.4610.9±3.908.1±1.729.4±3.12Years on GH10.1±4.929.4±3.957.1±1.508.1±2.97Years in study4.1±1.245.5±1.584.6±1.095.0±1.34*SDS* standard deviation score, *MPH* midparental height, *diffH-MPH* ~*SDS*~ the difference between the childs height~SDS~ vs MPH~SDS~^\*^ *p* = 0.001; ^\*\*^ *p* = 0.05

Normal or delayed infancy--childhood transition (ICT) {#Sec14}
-----------------------------------------------------

Age at ICT was available for 92 of the 104 children. A delayed ICT (DICT; ICT at \> 12 months of age) was found in 33 children (11 boys) \[[@CR25]\] (Additional file [1](#MOESM1){ref-type="media"}: Table S2).

### Familial short stature {#Sec15}

Midparental height (MPH) was below −2 SDS \[[@CR26]\] in 23 children (21 boys).

### Small for gestational age {#Sec16}

Twenty children (18 boys) were born small for gestational age with a birth length~SDS~ and/or birth weight~SDS~ \< −2 SDS \[[@CR27]\].

Statistical analyses {#Sec17}
--------------------

Statistical analyses were performed using the standard package SPSS version 20. Results are expressed as mean ± SD unless otherwise specified. Analyses concerning primary and secondary outcome variables were performed using non-parametric tests of the Wilcoxon type (Wilcoxon signed-rank test for within-group and Mann--Whitney *U* test for between-group comparisons). Safety analyses included all 149 children who received study drug. Analyses were performed for the ITT population and for boys in the PP population. Statistical significance was considered if *p* \< 0.05.

Simple bivariate correlation analyses were performed using Pearson's r.

*Stepwise multiple regression analysis* was used to analyse the influence of IGF-I variables on height gain and AH~SDS~. Data on birth characteristics and growth until 3 years of age, as well as baseline characteristics and prepubertal growth, were added as predictors in the analysis. Only variables entering the regressions below the significance level *p* \< 0.05 were used. No correction was performed for multiplicity. Stepwise forward regression analyses were performed with *p* \< 0.05 as entering criterion for predictors and *p* \< 0.10 for exclusion after inclusion in an earlier step.

Results {#Sec18}
=======

Patient characteristics {#Sec19}
-----------------------

The characteristics of the study group have recently been reported including 7 more children \[[@CR19]\] (see Table [1](#Tab1){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Table S1 for characteristics according to later randomization groups). Girls were younger than boys at GH start, 7.4 vs 10.2 years (*p* = 0.002) and also at study start, 12.3 vs 13.7 years (*p* = 0.001). Girls gained more height~SDS~ during prepuberty than boys, 2.2 vs 1.1 SDS, respectively (*p* = 0.0069) and less during puberty 0.2 vs 0.7, respectively (*p* = 0.029) (Table [1](#Tab1){ref-type="table"}; Additional file [1](#MOESM1){ref-type="media"}: Table S2).

### Comparison between children with DICT and normal ICT {#Sec20}

Patients with DICT had significantly lower IGF-I~SDS~ at GH start than patients with a normal ICT, −1.9 ± 2.0 vs −0.9 ± 0.9 (*p* = 0.014). See Additional file [1](#MOESM1){ref-type="media"}: Table S2 for baseline and study characteristics according to gender and ICT.

### Per-protocol population (PP) {#Sec21}

Comparing ITT and PP populations, similar results were found for the boys in both groups (data not shown); therefore, only the ITT population will be presented (Table [1](#Tab1){ref-type="table"}).

Prepubertal study results {#Sec22}
-------------------------

### IGF-I~SDS~ (Table [2](#Tab2){ref-type="table"}) IGFBP3~SDS~ (Table [3](#Tab3){ref-type="table"}) and IGF-I/IGFBP3 ratio~SDS~ (Table [4](#Tab4){ref-type="table"}) {#Sec23}

Table 2IGF-I during GH treatment according to randomization groupITTAll33 × 167 × 133 × 267 × 1 + 33 × 2IGF-I~SDS~nMean ± SDnMean ± SDnMean ± SDnMean ± SDMean ± SDAt GH start71−1.2 ± 1.5932−1.4 ± 1.5120−0.9 ± 1.6619−1.1 ± 1.66−1 ± 1.641^st^ year after GH start760.9 ± 1.71280.9 ± 1.37241 ± 1.95240 ± 1.890.9 ± 1.9ΔIGF-I~SDS~, 1^st^ year after GH start632.1 ± 1.48252.2 ± 1.37191.9 ± 1.94192.1 ± 1.12 ± 1.56Last pre-pubertal901.2 ± 1.23351.1 ± 1.15281.1 ± 1.33271.4 ± 1.261.3 ± 1.29IGF-I~SDS~ prepubertal level1000.8 ± 1.07370.6 ± 1.08300.9 ± 1.05331 ± 1.081 ± 1.06Study start1040.9 ± 1.21381 ± 1.02300.8 ± 1.33361 ± 1.290.9 ± 1.311^st^ year after study start1001.2 ± 1.07360.9 ± 0.88301.3 ± 1.15341.5 ± 1.13^\*^1.4 ± 1.13^\*\*^ΔIGF-I~SDS~ 1^st^ year after study start1000.3 ± 0.9836−0.1 ± 0.96300.5 ± 1.09^\*\*\*\*^340.4 ± 0.78^\*\*\*\*^0.5 ± 0.93^\*^IGF-I~SDS~ pubertal level1041 ± 0.95380.9 ± 0.67301.1 ± 1.14361.1 ± 1.031.1 ± 1.07ΔIGF.I~SDS~Pubertal level from study start1040.1 ± 0.9238−0.2 ± 0.86300.4 ± 1.1^\*\*\*^360.1 ± 0.75^\*\*\*\*\*^0.2 ± 0.92Before study stop1040.6 ± 1.36380.6 ± 1.18300.9 ± 1.29360.3 ± 1.570.6 ± 1.46After study stop65−0.4 ± 1.5423−0.1 ± 0.9118−0.3 ± 1.424−0.6 ± 2.04−0.5 ± 1.78*Δ* change, *IGF-I* insulin-like growth factor I, *SDS* standard deviation score^\*^ *p* = 0.007; ^\*\*^ *p* = 0.011; ^\*\*\*^ *p* = 0.014; ^\*\*\*\*^ *p* = 0.021; ^\*\*\*\*\*^ *p* = 0.028Table 3IGFBP3SDS during GH treatment according to randomization groupITTAll33 × 167 × 133 × 267 × 1 + 33 × 2IGFBP3~SDS~nMean ± SDnMean ± SDnMean ± SDnMean ± SDMean ± SDAt GH start71−0.3 ± 0.7632−0.4 ± 0.820−0.2 ± 0.6619−0.3 ± 0.83−0.3 ± 0.741^st^ year after GH start760.3 ± 0.82280.3 ± 0.73240.4 ± 0.87240.1 ± 0.870.2 ± 0.87ΔIGFBP3~SDS~ 1^st^ year after GH start630.6 ± 0.55250.7 ± 0.47190.7 ± 0.57190.5 ± 0.640.6 ± 0.6Prepubertal level1000.3 ± 0.54370.3 ± 0.54300.3 ± 0.63330.3 ± 0.630.3 ± 0.54Last pre-pubertal900.4 ± 0.55350.5 ± 0.49280.4 ± 0.48270.4 ± 0.680.4 ± 0.58Study start1040.4 ± 0.63380.4 ± 0.58300.3 ± 0.63360.4 ± 0.670.3 ± 0.651^st^ year after study start1000.3 ± 0.56360.3 ± 0.43300.3 ± 0.58340.4 ± 0.670.4 ± 0.63ΔIGFBP3~SDS~1^st^ year after study start1000 ± 0.4536−0.1 ± 0.49300 ± 0.51340 ± 0.360 ± 0.43Pubertal level1040.3 ± 0.56380.2 ± 0.45300.3 ± 0.62360.3 ± 0.630.3 ± 0.62ΔIGFBP3~SDS~ Pubertal level from study start104−0.1 ± 0.4338−0.2 ± 0.45^\*\*^300.0 ± 0.5136−0.1 ± 0.32−01 ± 0.42^\*^Before study stop1040.2 ± 0.77380.2 ± 0.82300.3 ± 0075360.1 ± 0.750.2 ± 0.75After study stop640.4 ± 0.8230.6 ± 0.57170.3 ± 0ö65240.2 ± 1.010.2 ± 0.87*Δ* change, *IGFBP3* IGF-binding protein 3, *SDS* standard deviation score\**p* = 0.029; \*\**p* = 0.038Table 4IGF-I/IGFBP3 RatioSDS during GH treatment according to randomization groupITTAll33 × 167 × 133 × 267 × 1 + 33 × 2IGF-I/IGFBP3 RatioSDSnMean ± SDNMean ± SDnMean ± SDnMean ± SDMean ± SDAt GH start71−1 ± 1.0832−1.1 ± 0.9420−0.8 ± 1.2419−0.8 ± 1.13−0.8 ± 1.171^st^ year after GH start760.6 ± 1.2280.5 ± 1.21240.6 ± 1.31240.7 ± 1.130.6 ± 1.21ΔRatio~SDS~ 1^st^ year after GH start631.5 ± 1.24251.6 ± 1.25191.2 ± 1.6191.6 ± 0.741.4 ± 1.24Prepubertal level1000.4 ± 0.95370.2 ± 0.98300.5 ± 0.97330.6 ± 0.890.6 ± 0.92Last pre-pubertal900.7 ± 1.18350.5 ± 1.11280.6 ± 1.24271 ± 1.170.8 ± 1.22Study start1040.5 ± 0.98380.6 ± 0.99300.3 ± 1.06360.6 ± 0.890.5 ± 0.971^st^ year after study start1000.9 ± 0.87360.6 ± 0.87300.9 ± 0.86341.2 ± 0.78^\*^1.1 ± 0.83^\*\*^ΔRatio~SDS~ 1^st^ year after study start1000.4 ± 0.93360 ± 0.95300.6 ± 1.03340.6 ± 0.73^\*\*\*\*^0.6 ± 0.87^\*\*\*^Pubertal level1040.9 ± 0.78380.7 ± 0.74300.9 ± 0.82331 ± 0.780.9 ± 0.79ΔRatio~SDS~ Pubertal level from study start1040.3 ± 0.89380.1 ± 0.92300.6 ± 1.04360.3 ± 0.660.5 ± 0.86Before study stop1040.5 ± 1.1380.5 ± 0.88300.7 ± 1.14360.3 ± 1.260.5 ± 1.21After study stop64−0.7 ± 1.0323−0.9 ± 0.7317−0.7 ± 1.1824−0.5 ± 1.16−0.6 ± 1.16*Δ* change, *IGF-I* insulin-like growth factor I, *IGFBP3* IGF-binding protein 3, *SDS* standard deviation score\**p* = 0.003; \*\**p* = 0.008; \*\*\**p* = 0.015; \*\*\*\**p* = 0.020

At GH start, mean IGF-I~SDS~ was −1.2 for the total study group, mean IGFBP3~SDS~ was −0.3 and mean IGF-I/IGFBP3 ratio~SDS~ was--1.0, and values did not differ between the three groups who later constituted the randomization groups (Additional file [1](#MOESM1){ref-type="media"}: Table S2).

The observed prepubertal mean change (∆) in IGF-I~SDS~ from GH start to the first year on GH therapy was 2.1 (Table [2](#Tab2){ref-type="table"}). The corresponding ∆IGFBP3~SDS~ was 0.6 (Table [3](#Tab3){ref-type="table"}) and the ∆IGF/IGFBP-3 ratio~SDS~ was 1.5 (Table [4](#Tab4){ref-type="table"}). The change in IGF-I~SDS~ relative to prepubertal mean level was 2.21, range −3.89 to 6.55.

### The relationship between prepubertal IGF variables and gain in height~SDS~ for all children on GH^33^ (Tables [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}) {#Sec24}

Table 5IGF-I variables and their correlations with different gain in height outcomesITTPubertal gain in height~SDS~Total gain in height~SDS~Prepubertal gain in height~SDS~IGF-I~SDS~nrprprpAt GH start710.02−0.370.002−0.530.0011^st^ year after GH start760.11−0.14−0.300.009AIGF-I~SDS~1^st^ year after GH start630.250.0530.420.0010.290.019Last pre-pubertal90−0.01−0.010.00IGF-I~SDS~ prepubertal level100−0.09−0.10−0.02Study start104−0.11−0.11−0.011^st^ year after study start1000.14−0.03AIGF-I~SDS~ 1^st^ year after study start1000.260.0100.10Pubertal level1040.210.034−0.08AIGF-I~SDS~Pubertal level from study start1040.350.0010.05Before study stop1040.260.008−0.170.083After study stop650.370.002−0.240.059*Δ* change, *IGF-I* insulin-like growth factor I, *SDS* standard deviation scoreTable 6IGFBP3 variables and their correlations with gain in height outcomesITTPubertal gain in height~SDS~Total gain in height~SDS~Prepubertal gain in height~SDS~IGFBP3~SDS~nrprprpAt GH start71−0.05−0.360.002−0.430.0011^st^ year after GH start760.09−0.220.052−0.390.001∆IGFBP3~SDS~1^st^ year after GH start630.130.290.0220.240.057Last pre-pubertal90−0.14−0.050.07IGFBP3~SDS~Prepubertal level100−0.12−0.110.00Study start104−0.09−0.030.061^st^ year after study start1000.09−0.02∆IGFBP3~SDS~1^st^ year after study start1000.200.0440.04Pubertal level1040.130.01∆IGFBP3~SDS~Pubertal level from study start1040.300.0020.05Before study stop1040.320.001−0.09After study stop640.350.005−0.17*Δ* change, *IGFBP3* IGF-binding protein 3, *SDS* standard deviation scoreTable 7IGF-I/IGFBP3 ratioSDS variables and their correlations with gain in height outcomesITTPubertal gain in height~SDS~Total gain in height~SDS~Prepubertal gain in height~SDS~IGF-I/IGFBP3 Ratio ~SDS~nrprprpAt GH start71−0,16−0,370,001−0,310,009Ratio~SDS~1^st^ year after GH start760,090,01−0,08∆Ratio~SDS~1^st^ year after GH start630,280,0260,420,0010,240,061Ratio~SDS~ Prepubertal level1000,03−0,09−0,10Last pre-pubertal900,080,01−0,06Study start104−0,02−0,190,048−0,160,0951^st^ year after study start1000,16−0,11∆Ratio~SDS~1^st^ year after study start1000,160,08Ratio~SDS~ Pubertal level1040,230,021−0,190,048∆Ratio~SDS~ Pubertal level after study start1040,220,0220,04Before study stop1040,07−0,14After study stop640,150,05*Δ* change IGF-I/IGFBP3 Ratio, *IGF-I* insulin-like growth factor I, *IGFBP3* IGF-binding protein 3, *SDS* standard deviation score

The group means for the three IGF variables at GH start were negatively correlated with prepubertal gain in height~SDS~ (IGF-I~SDS~*r* = −0.53, *p* = 0.001; IGFBP-3~SDS~*r* = −0.43, *p* = 0.001; IGF-I/IGFBP3 ratio~SDS~*r* = −0.31, *p* = 0.009) and with total gain in height~SDS~ (IGF-I~SDS~*r* = −0.37, *p* = 0.002; IGFBP3~SDS~*r* = −0.36, *p* = 0.002; IGF-I/IGFBP-3 ratio~SDS~*r* = −0.37, *p* = 0.001).

The first-year prepubertal ∆IGF-I~SDS~ was positively correlated with the prepubertal gain in height~SDS~ (Fig. [1](#Fig1){ref-type="fig"}), but did not correlate with the ∆IGFBP3~SDS~ or ∆IGF-I/IGFBP3 ratio~SDS~ after 1 year. All three prepubertal first-year ∆IGF variables were positively correlated with the total gain in height~SDS~ (∆IGF-I~SDS~*r* = 0.42, *p* = 0.001; ∆IGFBP3~SDS~*r* = 0.29, *p* = 0.022 and ∆IGF-I/IGFBP3 ratio~SDS~*r* = 0.42, *p* = 0.001).Fig. 1Prepubertal change in IGF-I~SDS~ in relation to prepubertal gain in height~SDS~. The change (∆) in IGF-I~SDS~ from GH start to prepubertal mean level in relation to prepubertal gain in height~SDS~ (*r* = 0.26, *p* \< 0.001)

Pubertal study results {#Sec25}
----------------------

### Pubertal IGF-I~SDS~, IGFBP3~SDS~ and IGF-I/IGFBP3 ratio~SDS~ mean study levels (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}) {#Sec26}

At study start, the group mean IGF-I~SDS~ was 0.9, the group mean IGFBP3~SDS~ was 0.4 and the group mean IGF-I/IGFBP3 ratio~SDS~ was 0.5. There were no differences between the three randomization groups.

The highest IGF-I~SDS~ was reached after 1 year in the study and the value subsequently decreased, i.e. the pubertal mean level was lower than the value at 1 year after randomization (see Table [2](#Tab2){ref-type="table"}).

The pubertal IGF-I~SDS~ for the total study group ranged from −2.1 to 3.5, with mean value being higher for the GH^67^group than for the GH^33^group, 1.1 vs 0.9, respectively (*p* = 0.031). The mean IGFBP3~SDS~ for the total study group was 0.3, with a range −1.2 to 1.3. For IGF-I/IGFBP3 ratio~SDS~, the mean was 0.9, with a range of −1.3 to 2.4. There were no significant differences between the randomization groups for IGFBP3~SDS~ or IGF-I/IGFBP3 ratio~SDS~.

### Dose-dependent change (∆) in IGF-I~SDS~ (Table [2](#Tab2){ref-type="table"}), IGFBP3~SDS~ (Table [3](#Tab3){ref-type="table"}) and IGF-I/IGFBP3 ratio~SDS~ (Table [4](#Tab4){ref-type="table"}) {#Sec27}

After the first year in the study, pubertal ∆IGF-I~SDS~ was significantly greater in the group randomized to GH^67^ than in the group still receiving the GH^33^ dose, 0.5 vs −0.1, respectively (*p* = 0.007; Table [2](#Tab2){ref-type="table"}).

A similar pattern was evident for the first year ∆IGF-I/IGFBP3 ratio~SDS~ for GH^67^ vs GH^33^, 0.6 vs 0, respectively (*p* = 0.015; Table [4](#Tab4){ref-type="table"}), but there was no change in IGFBP3~SDS~ after 1 year for any group (Table [3](#Tab3){ref-type="table"}).

When instead calculating the ∆SDS from study start to the mean pubertal level, again *∆*IGF-I~SDS~ was significantly greater for the GH^67^ vs GH^33^ group, 0.2 vs −0.2, respectively (*p* = 0.028), as shown in Fig. [2](#Fig2){ref-type="fig"}. When comparing the mean prepubertal and pubertal level of IGF-I~SDS~, IGFBP3~SDS~ and IGF-I/IGFBP3 ratio~SDS~ actually 47, 65 and 34 % respectively of children, equally for both dose groups, did not maintain the prepubertal level during puberty.Fig. 2Pubertal change in IGF-I~SDS~ according to randomization dose. Pubertal change (∆) in IGF-I~SDS~ from study start to pubertal mean level according to GH dose, 33 μg/kg/day vs 67 μg/kg/day. Box and whisker plots showing median, interquartile range (IQR) and values within ±1.5 IQR are given

### The relationship between IGF-I~SDS~, IGFBP3~SDS,~ IGF-I/IGFBP3 ratio~SDS~ and gain in height~SDS~, (Tables [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}) {#Sec28}

At randomization, the mean IGF-I~SDS~ and IGFBP3~SDS~ did not correlate with any of the height gain outcomes, whereas the mean IGF-I/IGFBP3 ratio~SDS~ was negatively associated with total height gain~SDS~ (*r* = −0.19, *p* = 0.048; Tables [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}).

For the individual, the pubertal ∆IGF~SDS~ from randomization was significantly correlated with the pubertal gain in height~SDS~ for both GH^33^ and GH^67^, *r* = 0.32 (*p* = 0.003) and *r* = 0.24 (*p* = 0.026) respectively (Fig. [3a](#Fig3){ref-type="fig"}). For the total study group, the IGF-I~SDS~ pubertal mean level correlated with the pubertal gain in height~SDS~, *r* = 0.17 (*p* = 0.034; Fig. [3b](#Fig3){ref-type="fig"}). The range in gain in height~SDS~ was wide, and there were no significant differences between the dose groups; therefore, the results from the total study group were used for further analyses.Fig. 3Pubertal change in IGF-I~SDS~ left and IGF-I~SDS~ pubertal mean level right according to pubertal gain in height~SDS~. a Change in pubertal IGF-I~SDS~ from study start to pubertal mean level in relation to pubertal gain in height~SDS~. Open circles GH^33^, *r* = 0.32, *p* \< 0.003; dots GH^67^. Correlation for total group: *r* = 0.24, *p* \< 0.026, with no significant slope for either GH^33^ or GH^67^ separately. b Attained IGF-I~SDS~ pubertal mean level in relation to pubertal gain in height~SDS~. Open circles GH^33^; dots GH^67^. Correlation for total group: *r* = 0.17, *p* \< 0.034, with no significant slope for either GH^33^ or GH^67^ separately

Disregarding randomization dose, the pubertal gain in height~SDS~ was positively correlated with the 1st year pubertal ∆IGF-I~SDS~ (*r* = 0.26, *p* = 0.010) and also with the ∆IGF-I~SDS~ to the pubertal mean level (*r* = 0.35, *p* = 0.001, Table [5](#Tab5){ref-type="table"}).

The first year pubertal ∆IGFBP3~SDS~ correlated with the pubertal gain in height~SDS~ (*r* = 0.20, *p* = 0.044), and the mean pubertal ∆IGFBP3~SDS~ correlated with the pubertal gain in height level (*r* = 0.30, *p* = 0.002; Table [6](#Tab6){ref-type="table"}). The attained mean pubertal level of IGFBP3~SDS~ was not correlated with height gain outcomes. The pubertal ∆IGF-I/IGFBP3 ratio~SDS~ was correlated (*r* = 0.22, *p* = 0.022) with the pubertal gain in height~SDS~. The attained mean pubertal level of IGF-I/IGFBP3 ratio~SDS~ correlated with the pubertal gain in height~SDS\ (~*r* = 0.23, *p* = 0.021) and with total gain in height~SDS~ (*r* = −0.19, *p* = 0.048; Table [7](#Tab7){ref-type="table"}).

Multivariate regression (Tables [8](#Tab8){ref-type="table"} and [9](#Tab9){ref-type="table"}) {#Sec29}
----------------------------------------------------------------------------------------------

Table 8Multivariate analyses on height outcomes with GH 67 μg/kg/day and IGF variables availableITTBSEBpR^2^Total gain in height~SDS~(Constant)1.230.1480.00028IGF-I~SDS~ 1 year after GH start0.240.0580.000∆IGF-I~SDS~ pubertal level from study start0.290.0930.003Pubertal gain in height~SDS~(Constant)0.420.1210.00126∆IGF-I~SDS~ pubertal level from study start0.340.0860.000∆IGF-I/IGFBP3 ratio~SDS~ 1 year after GH start0.200.0630.002Prepubertal gain in height~SDS~(Constant)0.910.1360.00021IGF-I~SDS~ at GH start−0.280.0690.000*Δ* change, *IGF-I* insulin-like growth factor I, *IGFBP3* IGF binding protein 3, *SDS* standard deviation scoreTable 9Multivariate analyses on height outcomes with all variables availableITTBsebPR^2^, %Total gain in height~SDS~(Constant)0.190.2000.34063Prepubertal gain in height~SDS~0.550.0850.000Bone age delay at GH start−0.250.0720.001∆IGF-I/IGFBP3 ratio~SDS~ 1 year after GH start0.200.0650.003High dose0.380.1610.023Pubertal gain in height~SDS~(Constant)0.310.1830.09546Bone age delay study start−0.260.0690.000Years on GH prepubertal−0.110.0290.001∆IGF-I~SDS~ 1 year after GH start0.140.0490.008∆IGF-I~SDS~ pubertal level from study start0.190.0830.025Prepubertal gain in height~SDS~(Constant)−0.630.0890.00094Years on GH, prepubertal0.280.0130.000∆Height~SDS~ 1 year after GH start0.690.0740.000∆IGF-I/IGFBP3ratio~SDS~ 1 year after GH start0.120.0290.000Gender (female)0.530.1000.000Bone age delay at GH start−0.100.0290.002∆IGFBP3~SDS~ 1 year after GH start0.140.0620.030*A* change, *IGF-I* insulin-like growth factor I, *IGFBP3* IGF-binding protein 3, *Ratio* IGF-I/IGFBP3 Ratio, *SDS* standard deviation score

### Variance in pubertal ∆IGFs {#Sec30}

In total, 39 % of the variation in pubertal ∆IGF-I~SDS~ was explained by the variable 'IGF-I~SDS~ at study start'; the lower the value at study start, the greater the increase during puberty. Similarly, for pubertal ∆IGFBP3~SDS~, 28 % (also including age, +) was explained and for ∆IGF-I/IGFBP3 ratio~SDS~ 40 % was explained.

### Variance in gain in height~SDS~ with only IGF variables available (Table [8](#Tab8){ref-type="table"}) {#Sec31}

With only the IGF variables available, 26 % of the variation in *pubertal* gain in height~SDS~ could be explained by 'pubertal (from study start to pubertal level) ∆IGF-I~SDS~' and 'first year prepubertal ∆IGF-I/IGFBP3 ratio~SDS~'. For *total* gain in height~SDS~, 28 % of the variation was explained by 'prepubertal IGF-I~SDS~ first year after GH start' and 'pubertal ∆IGF-I~SDS~'. Regarding the variation in *prepubertal* gain in height~SDS,~ 21 % was explained by 'IGF-I~SDS~ at GH start' (the lower the better).

### Variance in gain in height~SDS~ with all variables available (Table [9](#Tab9){ref-type="table"}) {#Sec32}

The variables are presented in the order they entered in the analyses. For the *pubertal gain* in height~SDS~, 46 % of the variation could be explained by 'bone age at study start' (−), 'prepubertal years on GH' (−), '∆IGF-I~SDS~ 1 year after GH start' (+) and 'pubertal ∆IGF-I~SDS~ (pubertal level from study start).

For the variation in *total gain* in height~SDS~. 63 % could be explained by the variables 'prepubertal gain in height~SDS~' (+), 'bone age at GH start' (−),' ∆IGF/IGFBP3 ratio~SDS~ 1 year after GH start' (+) and 'high GH dose' (+).

In the analysis of *prepubertal gain* in height~SDS~, 94 % of the variation was explained by 'number of prepubertal years on GH', 'first year ∆height~SDS~', 'first year ∆IGF-I/IGFBP3 ratio~SDS~'~,\ '~gender' (girl +), 'bone age at GH start' (the greater the delay the better) and 'first year ∆IGFBP3~SDS~'.

Discussion {#Sec33}
==========

Changes in IGFs relate to prepubertal and pubertal height gain {#Sec34}
--------------------------------------------------------------

The present analysis reported results for multiple variables including IGF-I, IGFBP3 and their ratio in IIGHD children from the start of GH treatment until AH, and the relationship of IGFs to both the prepubertal period when all participants received the same 33 μg/kg/d and the pubertal period when they were randomised to 33 or 67 μg/kg/d. The analysis focused on GH responsiveness as estimated by changes and obtained prepubertal and pubertal levels of IGF-I~SDS~, IGFBP3~SDS~ and IGF-I/IGFBP3 ratio~SDS~. The main findings were: a significant dose-dependent (33 or 67 μg/kg/d) change in IGF-I~SDS~ from randomization at onset of puberty to mean pubertal study level, and a positive correlation between this pubertal ∆IGF-I~SDS~ and the pubertal gain in height~SDS~. The greatest change was found in IGF-I followed by a less pronounced change in IGF-I/IGFBP3 ratio, while IGFBP3 values remained more stable. The GH dose given during puberty did not maintain the mean prepubertal IGF-I level, suggesting that some children may have benefitted from a higher dose in order to undergo a pubertal growth spurt of normal magnitude \[[@CR19]\]. The need for wide-ranging individual GH dosing in order to promote growth has previously been demonstrated during prepuberty \[[@CR28]\], here we find similar requirements when studying IGFs and growth during the pubertal period. Actually, GH responsiveness in the present study group was so broad that the low dose was too high for some individuals while the high dose was too low for others in order to attain IGFs and pubertal height gain within normal range.

Prepubertal responsiveness to GH, reflected by a significant increase in IGFs after GH start \[[@CR5], [@CR28]\], has previously been reported to be of great importance for the short-term growth response; in the present analysis it was found to be important also for the total gain in height. This highlights the importance of individual GH dosing from treatment start, with the available prediction models presently being the best tools with which to estimate outcomes \[[@CR29], [@CR30]\]. Thus, when an increased GH dose during puberty induced a greater ∆IGF-I~SDS~, this resulted in a greater pubertal height gain than observed with a standard GH dose for most subjects. This finding has previously been reported in non-GHD subjects, with ∆IGF-I~SDS~ found to be the most reliable variable correlating with pubertal gain in height~SDS~ \[[@CR17]\]. Thus, there is no principal difference in the IGF-I response and growth response between these two aetiologies of short stature, although the magnitude of GH responsiveness is higher in the GH-deficient than in the non-GH-deficient group \[[@CR5], [@CR31]\].

GH has effects on longitudinal bone growth both directly at the growth plate and locally mediated through IGF-I \[[@CR32], [@CR33]\]. The increase in IGF-I level as a response to GH treatment could be seen as a sign of GH responsiveness \[[@CR5]\]. GH/IGF-I responsiveness varies not only between individuals but also between tissues within an individual, e.g. more GH is needed to produce an effect on IGF-I production than for longitudinal bone growth \[[@CR34]\].

Pubertal response in IGFs {#Sec35}
-------------------------

In the present analyses, there was a significant difference in pubertal IGF-I~SDS~ between randomization groups, with higher mean values in the GH^67^ than the GH^33^ group. This finding supports results from the study of Mauras et al. \[[@CR15]\] who reported that by using higher GH doses during puberty (100 vs 42 μg/kg/d), a significantly higher pubertal gain in height~SDS~ was found, as well as a higher but non-significant IGF-I response in the high- relative to the low-dose group. The difference in importance of IGF-I in relation to our study may be due to differences in IGF-I references: we used our in-house reference with SDS considering gender, age and pubertal stage \[[@CR12]\]. In the study by Sas et al. using GH doses corresponding to 25 or 50 μg/kg/d until AH, the mean increase in IGF-I~SDS~ after 1 year on GH was twice as high for the high- versus the low-dose group, although the difference did not reach significance. The relationship between IGF-I~SDS~ and growth response was not given \[[@CR16]\]. Neither IGFBP3 nor IGF-I/IGFBP3 ratio was measured in these two published trials.

### The multivariate analyses {#Sec36}

In agreement with our findings in non-GH-deficient children \[[@CR17]\], among the IGF-variables also in the present study, the pubertal ∆IGF-I~SDS~ was found to be the most informative variable, and more important than the level per se, for explaining the variance in both pubertal and total gain in height~SDS~ . When all variables were allowed, bone age delay and less prepubertal years on GH in addition to ∆IGF-I~SDS~ was positive for *pubertal gain in height*~*SDS*~. This may be explained by some remaining catch-up growth occurring during puberty in some study subjects, even though all children had been treated with GH for at least 1 year before randomization.

The explanatory variables for pubertal gain in height were in accordance with those identified within the KIGS observational study, except that bone age was selected in our study and chronological age in the KIGS study \[[@CR14]\]. This difference may be because bone age was estimated by a single radiologist in our trial which increased the quality and consistency of this variable.

For *total gain in height* in the present study, a GH dose high enough to result in a substantial prepubertal ∆IGF-I/IGFBP-3 ratio~SDS~ was favourable. The high dose was set at 67 μg/kg/d even though the present results suggest that nearly 50 % of the children could have benefitted from an even higher dose. We need to remember that at the time of study design, there were limited data on GH treatment doses and safety, and no tools available for estimation of individual GH responsiveness such as the prediction models for GH growth response \[[@CR30], [@CR35]\].

Prepubertal response {#Sec37}
--------------------

Mean IGF-I~SDS~, IGFBP3~SDS~ and IGF-I/IGFBP3 ratio~SDS~ at GH start were in the low/normal range. Lower IGF levels at baseline were associated with greater changes after 1 year of GH therapy. We found a strong negative bivariate linear correlation between low baseline IGF-I~SDS~, IGFBP3~SDS~, their ratio~SDS~ and both prepubertal and total gain in height~SDS~. The prepubertal IGF-I response and its relationship to gain in height is already well known \[[@CR3]--[@CR5], [@CR36]\]. It was previously reported that the observed prepubertal 1-year growth response makes it possible to estimate the full prepubertal gain in height in both children with GHD and in non-GH-deficient groups \[[@CR37]\]. Knowledge of the relationship between the change in IGFs and total gain in height~SDS~ can now be added, and highlights the importance of considering prepubertal GH responsiveness and achieving a greater first year ∆IGFs when selecting GH dose. The ∆IGF-I~SDS~, ∆IGFBP3~SDS~ and ∆IGF/IGFBP3 ratio~SDS~ 1 year after GH start mirrored individual GH responsiveness as measured by IGF-I generation. This supports results from 1-year non-randomized observations in GH-deficient and non-GH-deficient groups \[[@CR8], [@CR9], [@CR36]\].

In our analyses, prepubertal IGF-I~SDS~ did not correlate with gain in height. This is in contrast to the findings of the study by Cohen et al. who found a relationship between IGF-I level (the higher the better) and height gain in prepubertal children treated for 2 years with IGF-I-targeting GH doses \[[@CR28]\]. The difference in results may be explained by differences in study design, mainly in terms of inclusion criteria and dose ranges. However, in both studies the ∆IGF-I~SDS~ was found in multivariate analyses to be the most informative variable explaining growth response.

### The multivariate analyses {#Sec38}

In multivariate regression analyses using only IGF variables, baseline IGF-I~SDS~ alone explained 21 % of the variation in prepubertal gain in height. When adding auxological variables, the variation explained improved to 94 % with the following important variables: bone age delay at GH start (more delay better growth) and prepubertal years on GH (more years, more growth). Many prepubertal years on GH are also a sign of GHD (being young at diagnosis was associated with more severe GHD).

Different information from IGFBP3~SDS~ and IGF/IGFBP3 ratio~SDS~ {#Sec39}
----------------------------------------------------------------

IGFBP3 and IGF-I/IGFBP3 ratio are not routinely monitored during GH treatment. IGFBP3 is less sensitive to short-term nutritional variations and diseases than IGF-I and could therefore be valuable when monitoring efficacy of and compliance with GH treatment \[[@CR38]\]. In addition, a more pronounced change in IGF-I relative to IGFBP3 results in an increased IGF-I/IGFBP3 ratio \[[@CR22], [@CR39]\], which can be seen as an indicator of increased IGF-I bioavailability \[[@CR40]\]. In the present study, changes in IGF-I/IGFBP3 ratio~SDS~ followed changes in IGF-I, and correlated significantly with both pubertal and total gain in height~SDS~. In the multivariate regression analysis, prepubertal ∆IGF-I/IGFBP3 ratio~SDS~ was selected for explanation of variance in both prepubertal and total gain in height~SDS~. ∆IGF-I/IGFBP3 ratio~SDS~ may be a result of a synergistic effect of IGF-I and IGFBP3 during GH therapy \[[@CR41]\], where IGFBP3 modulates the actions of IGF-I, as well as having an independent effect \[[@CR40]\]. To our knowledge, longitudinal observation of IGF-I/IGFBP3 ratio~SDS~ during pubertal growth in a population with IIGHD has not previously been reported.

IGFs markers for safety {#Sec40}
-----------------------

In the present study no dose-dependent adverse event involving carbohydrate metabolism was observed, which confirms previous studies with high GH doses \[[@CR15], [@CR16], [@CR42], [@CR43]\]. However, a modest association between increased circulating level of IGF-I and an increased risk of common cancers in adult has been reported \[[@CR1], [@CR44]\]. Most circulating IGF-I is bound to IGFBP3 and to the acid labile subunit (ALS) \[[@CR45]\], therefore, the IGF-I/IGFBP3 ratio~SDS~ could reflect the tissue availability of IGF-I and its correlation with free IGF-I \[[@CR39], [@CR40], [@CR46]\]. Our data showed no dose-dependent differences in pubertal IGF-I/IGFBP3 ratio~SDS~, only a broad range of IGF-I~SDS~ and IGFBP3~SDS~, highlighting that GH dosing needs to be individualized \[[@CR31]\].

Compliance {#Sec41}
----------

In the present study, stable IGF-I~SDS~ and IGFBP3~SDS~ concentrations were observed, which is a sign of good compliance \[[@CR38], [@CR47]\]. There were more than 10 samples for each patient and nearly 2000 samples in the total analysis. Only 8 single samples were excluded due to suspected poor compliance.

Poor compliance could be a factor that underestimates the study results; both in terms of IGF-I and growth responses. Pubertal teenagers are known to have the lowest treatment compliance due to many factors, not least psychological \[[@CR48], [@CR49]\]. In order to promote good compliance in our study, all participants were responsible for their own injections and were followed every third month. At each visit they were invited to discuss their treatment with their endocrine team \[[@CR50]\].

The heterogeneity of the study group {#Sec42}
------------------------------------

The study group was heterogeneous, including patients with classic GHD, partial GHD and some short boys with low GH secretion in the late prepubertal period \[[@CR51]\], and there was a broad range of IGF-I~SDS~ and IGFBP3~SDS~ at baseline. This reflects the reality in daily clinical practice and allows results to represent patients with a wider range of baseline levels of GH secretion and a broad range in GH responsiveness.

Limitations of the study {#Sec43}
------------------------

The study was designed before individual GH responsiveness was broadly considered. Children were randomized to weight-based dosing and 38 % of patients decided to reduce or stop GH treatment before AH was reached due to satisfaction with their attained height, which was accepted by the protocol. However, the combination of the limited number of patients in the treatment groups, the broad variability in their growth responses, and the premature stop/reduction of GH dose will underestimate the result of the study regarding changes in IGF-I~SDS~, IGFBP-3~SDS~ and IGF-I/IGFBP-3 ratio~SDS~, as well as the dose-dependent effect on pubertal gain in height~SDS~.

The onset of puberty was defined by clinical signs in the present trial, making it possible that some pubertal growth had occurred before randomization, thus leading to underestimation of the pubertal IGF-I response and gain in height.

Girls constituted a small group in the current analyses. The low number of girls in each dose group does not allow conclusions about use of an even higher GH dose during puberty in girls.

Conclusion {#Sec44}
==========

In the present analysis we studied GH responsiveness estimated on the obtained levels and change of IGF-I~SDS~, IGFBP3~SDS~ and IGF-I/IGFBP-3 ratio~SDS~ and the associated growth response in children with IIGHD randomized in puberty to different weight-based GH dose regimens. Thereby, the relationship of IGFs to gain in height~SDS~ during both the prepubertal and pubertal growth phases could be explored. The prepubertal increase in IGFs associated with a 33 μg/kg/d GH dose and the GH dose-dependent (33 or 67 μg/kg/d) pubertal increase in IGF-I, were both important variables that explained the total gain in height: the higher the prepubertal GH responsiveness, the greater the total gain in height~SDS~. Our hypothesis that increased GH dose during puberty would result in a more pronounced IGF-I response and greater growth was found to be valid: the higher GH dose during puberty was followed by both higher IGF-I~SDS~ and a greater gain in height~SDS~ than observed in patients receiving the lower GH dose. Thus, of great importance in the clinical setting: the individual who remains short at onset of puberty require a GH dose increase great enough to result in an increment in IGF-I in order to gain any height~SDS~ during puberty.

Additional file {#Sec45}
===============

Additional file 1:**Table S1.** Baseline characteristics according to randomization group: at birth, at GH start and at study start. **Table S2.** Baseline characteristics according to gender and infancy--childhood transition (ICT): at birth, at GH start, at study start and at adult height. (PDF 222 kb)

AITT

:   Arginine--insulin tolerance test

AH

:   Adult height

BL

:   Birth length

BMI

:   Body mass index

BW

:   Body weight

BA

:   Bone age

DICT

:   Delayed infancy--childhood transition, ICT \>12 months after birth

diffH-MPH~SDS~

:   The difference between the child's Height~SDS~ vs MPH~SDS~

GH

:   Growth hormone

GHD

:   Growth hormone deficiency

GH^33x1^

:   GH, Standard dose 33 μg/kg once daily injection

GH^33x2^

:   GH, 33 μg/kg twice daily injection

GH^67x1^

:   GH, 67 μg/kg once daily injection

GH^67^

:   GH 33×2 and 67×1, the high-dose group

GH~max~24h

:   Maximum GH level during a spontaneous 24h GH profile

GH~max~AITT

:   Maximum GH level during an AITT

ICT

:   Infancy--childhood transition, months

IGF-I

:   Insulin-like growth factor I

IIGHD

:   Idiopathic isolated growth hormone deficiency

IGFBP-3

:   Insulin-like growth factor-binding protein 3

IRP

:   International reference preparation

ITT

:   Intention-to-treat

MPH

:   Midparental height

PP

:   Per-protocol

RIA

:   Radioimmuno assay

SDS

:   Standard deviation score

WHO

:   World Health Organization
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